x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Smart Biotech Scientist | The CMC and Biomanufacturing Podcast for Bioprocess Development and Manufacturing Leaders

David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist

The go-to CMC and bioprocessing podcast for process development scientists and CMC leaders scaling biologics into regulatory-ready therapies with less trial and error.Practical, execution-focused guidance on CMC development, tech transfer, scale-up, GMP readiness, CDMO partnerships, and manufacturing economics.Hosted by Dr. David Brühlmann, CMC strategist, former Bioprocess Innovation Manager at Merck, PhD in glycoengineering, and close to 20 years of biomanufacturing experience. Smart Biotech

science life sciences

All Episodes

17:56

218: Silkworm Biomanufacturing: From Ancient Silk...

Smart Biotech Scientist | The CMC and... ·

2026/01/08

For generations, silkworm pupae were discarded as waste from silk production. Now, KAICO is proving these organisms can function as highly efficient protein factories—producing complex vaccine antigens at yields and costs that challenge conventional bioreactor-based manufacturing. With a PCV2 oral vaccine already registered in Vietnam and a human norovirus vaccine preparing for Phase I clinical trials, the silkworm platform is moving from proof-of-concept to commercial reality. In Part 2, Mas...

en-us

25:29

217: Silkworm Biomanufacturing: From Ancient Silk...

Smart Biotech Scientist | The CMC and... ·

2026/01/06

For over 4,000 years, silkworms have connected civilizations through ancient trade routes. Now, KAICO Ltd., a Japanese biotech spin-off from Kyushu University, is transforming these creatures into living bioreactors capable of producing complex recombinant proteins and vaccine antigens—without the bioreactors, expensive media, or massive water consumption of conventional platforms. Masafumi Osawa, Business Development Lead at KAICO, brings an unconventional path to biotech. Trained in cultura...

en-us

18:33

216: From Data Silos to Autonomous Biomanufacturing:...

Smart Biotech Scientist | The CMC and... ·

2025/12/18

Biomanufacturing has always dealt with the challenge of turning vast, complex datasets and intricate production steps into life-changing therapies. But when batch records multiply and process deviations loom, how do biotech teams make sense of it all? In this episode, we move beyond theory to the nuts and bolts of how AI - when thoughtfully deployed - can turn bioprocessing chaos into actionable intelligence, paving the way for the factory of the future. Our guest, Ilya Burkov, Global Head of...

en-us

21:34

215: From Data Silos to Autonomous Biomanufacturing:...

Smart Biotech Scientist | The CMC and... ·

2025/12/16

Across biotech labs, researchers swim in oceans of process data: sensor streams, run records, engineering logs, and still, crucial decisions get stuck in spreadsheets or scribbled into fading notebooks. The challenge isn’t having enough information, it's knowing which actions actually move the needle in cell culture productivity, process stability, and faster timelines. This episode, David Brühlmann brings on Ilya Burkov, Global Head of Healthcare and Life Sciences Growth at Nebius AI. With a...

en-us

14:49

214: From Developability to Formulation: How In...

Smart Biotech Scientist | The CMC and... ·

2025/12/11

Computational methods can predict stability issues before the lab. But how do you actually implement these approaches in your formulation workflow? From excipient selection to long-term stability prediction, in silico tools are transforming how biotech teams develop robust formulations while reducing costly trial-and-error cycles. In Part 2, Giuseppe Licari, Principal Scientist in Computational Structural Biology at Merck KGaA, returns to share practical implementation strategies for integrat...

en-us

25:21

213: From Developability to Formulation: How In...

Smart Biotech Scientist | The CMC and... ·

2025/12/09

What if you could predict formulation failures before ever touching a pipette? Computational approaches are revolutionizing biologics development, replacing trial-and-error experimentation with predictive intelligence that catches stability issues early and accelerates your path from candidate selection to clinic. In this episode, David Brühlmann welcomes Giuseppe Licari, Principal Scientist in Computational Structural Biology at Merck KGaA. A chemist by training, Giuseppe transitioned from w...

en-us

22:13

212: When the Innovator Becomes the Patient:...

Smart Biotech Scientist | The CMC and... ·

2025/12/04

What happens when cell therapy innovation meets real patient urgency? In this conversation, the barriers between scientist and patient all but vanish, bringing clarity—and a new sense of mission—to some of the biggest problems facing advanced therapy manufacturing and delivery. Meet Jesús Zurdo, a biotech leader whose three decades of experience in innovation took on a whole new perspective when he became a leukemia patient himself. Seamlessly straddling the worlds of industry and patient car...

en-us

21:25

211: When the Innovator Becomes the Patient:...

Smart Biotech Scientist | The CMC and... ·

2025/12/02

Real progress in cell and gene therapy shouldn’t be measured solely by scientific innovation, but by whether those innovations actually reach the patients who need them most. In this episode, David Brühlmann sits down with Jesús Zurdo, a scientist who’s spent three decades engineering life-changing biotechnologies, but whose outlook on the field shifted dramatically after becoming a leukemia patient himself. With experience on both sides of the system, Jesús Zurdo brings a rare, unfiltered pe...

en-us

21:49

210: From Batch to Continuous: Building Innovation...

Smart Biotech Scientist | The CMC and... ·

2025/11/27

From pandemic-speed vaccine deployment to AI-powered process control, what separates hype from real manufacturing transformation? The biotech industry faces a fundamental challenge: how do you maintain rigorous quality standards while accelerating development timelines, personalizing therapies, and adopting transformative technologies? The answer isn't found in chasing every innovation trend, it's in understanding which changes create genuine value and when to implement them across the produc...

en-us

29:14

209: From Batch to Continuous: Building Innovation...

Smart Biotech Scientist | The CMC and... ·

2025/11/25

The biotech industry operates under constant tension: we work with products that directly impact human lives, demanding rigorous controls and validation at every step. Yet standing still means falling behind. The question isn't whether to innovate, it's how to do it without compromising the quality and safety standards that define our industry. Irina Ramos has lived this paradox throughout her career. As a downstream processing leader who's guided CMC programs from early development through g...

en-us

22:37

208: Cryogenic Infrared Ion Spectroscopy: From Mass...

Smart Biotech Scientist | The CMC and... ·

2025/11/20

What if you could analyze every metabolite, glycan variant, and unknown impurity in your bioprocess sample—not just the targets you're looking for, but everything that's actually there? Cryogenic infrared ion spectroscopy combined (CIRIS) with AI-powered analysis transforms untargeted screening from aspiration to reality. This episode moves from fundamental principles to practical applications. While Part 1 established how CIRIS overcomes mass spectrometry's structural limitations, Part 2 rev...

en-us

22:35

207: Cryogenic Infrared Ion Spectroscopy: From Mass...

Smart Biotech Scientist | The CMC and... ·

2025/11/18

What if you could identify every structural variant in your biologics—without ambiguity, without massive sample requirements, and without the guesswork that plagues traditional mass spectrometry? Cryogenic infrared ion spectroscopy (CIRIS) makes it possible, transforming molecular characterization from frustrating puzzle to precise science. Today's guest, Professor Tom Rizzo, bridges the gap between academic innovation and industrial application. As former Dean of the School of Basic Sciences...

en-us

17:45

206: Process Economics Decoded: How to Model...

Smart Biotech Scientist | The CMC and... ·

2025/11/13

Carbon neutrality goals are everywhere in biopharma. But how do you actually measure and reduce your true environmental impact when data gaps and baseline differences make comparisons so tough? In this episode, David Brühlmann talks with Niklas Jungnelius, Cytiva’s expert in process modeling and sustainability, who’s spent years uncovering what really drives emissions and how small process tweaks can deliver big results. Niklas goes beyond the numbers, challenging assumptions and showing how ...

en-us

25:35

205: Process Economics Decoded: How to Model...

Smart Biotech Scientist | The CMC and... ·

2025/11/11

Your Manufacturing Decisions Are Costing You More Than You Think Every bioreactor decision. Every scale-up choice. Every facility investment. They're all silently writing checks your process might not be able to cash. The difference between a profitable biologics program and one that bleeds capital? Process economic modeling, the analytical framework that reveals exactly where your money goes and why. In this episode of the Smart Biotech Scientist Podcast, David Brühlmann talks with Niklas Ju...

en-us

20:13

204: Mastering CRO Selection: Essential Questions for...

Smart Biotech Scientist | The CMC and... ·

2025/11/06

Cell and gene therapies are transforming modern medicine, but their path to market is fast and complex. They often jump from small trials to global launch at record speed, putting pressure on analytics, supply chains, and partnerships. Success depends on making smart choices about what to build in-house and what to entrust to expert partners. Daniel Galbraith knows these challenges intimately. With decades of hands-on experience and as Chief Scientific Officer at Solvias, Daniel has witnessed...

en-us

28:40

203: Mastering CRO Selection: Essential Questions for...

Smart Biotech Scientist | The CMC and... ·

2025/11/04

Finding an analytical CRO that's truly invested in your success, not just processing samples, makes all the difference in CMC development. In this episode, host David Brühlmann talks with Daniel Galbraith, Chief Scientific Officer at Solvias, about the essential questions and mindset that lead to breakthrough CRO partnerships. With nearly three decades in analytical development, spanning monoclonal antibodies, biosimilars, and cell and gene therapies, Daniel reveals what separates CROs who be...

en-us

24:00

202: Fighting Antimicrobial Resistance: How AI Cuts...

Smart Biotech Scientist | The CMC and... ·

2025/10/30

What if the answer to battling antibiotic-resistant infections isn’t a new antibiotic, but harnessing viruses that have been quietly dominating bacterial populations? Bacteriophages, viruses that target and kill bacteria, have been saving lives for a century, but their true potential is only now being unlocked by modern machine learning. The race isn’t just about discovering effective phages; it’s about deploying the right therapy, personalized to the patient, before time runs out. On this ep...

en-us

24:46

201: Fighting Antimicrobial Resistance: How AI Cuts...

Smart Biotech Scientist | The CMC and... ·

2025/10/28

Antibiotic resistance isn’t just a looming problem. It’s a global crisis. Every year, more than one million people die directly from resistant infections, and another 5 million die indirectly. Routine infections are becoming life-threatening, and healthcare systems worldwide are under pressure. Despite decades of warnings, pharmaceutical solutions are falling behind, while “superbugs” continue to outpace new drug development. If trends continue, by 2050, antibiotic resistance could claim 10 m...

en-us

20:32

200: Mastering Quality by Design: From Product...

Smart Biotech Scientist | The CMC and... ·

2025/10/23

Your process works perfectly at two-liter bench scale. Then you hit fifty liters and titer drops 20%. By two hundred liters, aggregation appears and charge variants shift. Your management team asks: "How long to fix this?" The honest answer? Three to twelve month, because you're flying blind. In Part 2 of this Quality by Design Master Class, David Brühlmann reveals why scale-up chaos isn't inevitable. It's a solvable engineering problem. Drawing on experience leading bioprocess innovation at ...

en-us

19:44

199: Mastering Quality by Design: From Product...

Smart Biotech Scientist | The CMC and... ·

2025/10/21

Over 40% of biotherapeutic failures during clinical development stem from stability problems—and most trace back to protein aggregation that could have been prevented. In this episode of the Smart Biotech Scientist Podcast, David Brühlmann exposes the hidden manufacturing crisis that derails promising biologics programs and delivers the systematic Quality by Design framework that elite biotech companies use to build quality into every process step. David brings two decades of bioprocess exper...

en-us

206 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter